SGLT2抑制剂对停用RAS阻断剂的影响:CREDENCE与DAPA-CKD联合分析
该研究联合分析CREDENCE和DAPA-CKD两项随机双盲安慰剂对照试验,评估SGLT2抑制剂对白蛋白尿性CKD患者停用RAS阻断剂的影响。中位随访2.2年,8483例中740例(8.7%)停用RAS阻断剂,SGLT2抑制剂组停用相对风险降低15%(HR 0.85,95%CI 0.74-0.99),在尿白蛋白肌酐比≥1000 mg/g患者中效应更明显(汇总HR 0.77,95%CI 0.63-0.94)。
要点
- SGLT2抑制剂使白蛋白尿性CKD患者停用RAS阻断剂的相对风险降低15%(HR 0.85)。
- 尿白蛋白肌酐比≥1000 mg/g患者中SGLT2抑制剂效应更明显(汇总HR 0.77)。
- 两项试验间效应一致(P-异质性=0.92)。
核心结论
- 在白蛋白尿性CKD伴或不伴2型糖尿病患者中,SGLT2抑制剂促进RAS阻断剂的使用。
研究设计与样本
- CREDENCE和DAPA-CKD两项随机、双盲、安慰剂对照、事件驱动试验的联合分析,共8483例白蛋白尿性CKD患者,中位随访2.2年。
主要发现
- 随访期间740/8483例(8.7%)患者停用RAS阻断剂。
- 随机接受SGLT2抑制剂的患者停用RAS阻断剂的相对风险降低15%(HR 0.85,95%CI 0.74-0.99),两项试验间效应一致(P-异质性=0.92)。
- 基线尿白蛋白肌酐比≥1000 mg/g患者中,SGLT2抑制剂对RAS阻断剂停用的相对效应更明显(汇总HR 0.77,95%CI 0.63-0.94;P-异质性=0.009)。
临床怎么用
- 在白蛋白尿性CKD伴或不伴2型糖尿病患者中,SGLT2抑制剂可能有助于维持RAS阻断剂的持续使用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are foundational therapy for CKD but are underused, in part because they are frequently withheld and not restarted due to hyperkalemia, AKI, or hospitalization. Consequently, ensuring persistent use of ACE inhibitors and ARBs in CKD has long been a major clinical priority. In this joint analysis of the CREDENCE and DAPA-CKD trials, the relative risk of discontinuation of ACE inhibitors and ARBs was reduced by 15% in patients randomized to sodium-glucose cotransporter 2 (SGLT2) inhibitors. This effect was more pronounced in patients with urine albumin:creatinine ratio ≥1000 mg/g, for whom the absolute benefits of these medications are the greatest. These findings indicate that SGLT2 inhibitors may enable better use of ACE inhibitors and ARBs in patients with CKD. BACKGROUND: Strategies to enable persistent use of renin-angiotensin system (RAS) blockade to improve outcomes in CKD have long been sought. The effect of SGLT2 inhibitors on discontinuation of RAS blockade has yet to be evaluated. METHODS: We conducted a joint analysis of canagliflozin and renal events in diabetes with established nephropathy clinical evaluation (CREDENCE) and dapagliflozin and prevention of adverse outcomes in CKD (DAPA-CKD), two randomized, double-blind, placebo-controlled, event-driven trials of SGLT2 inhibitors in patients with albuminuric CKD. The main outcome was time to incident temporary or permanent discontinuation of RAS blockade, defined as interruption of an ACE inhibitor or ARB for at least 4 weeks or complete cessation during the double-blind on-treatment period. Cox regression analyses were used to estimate the treatment effects from each trial. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were pooled with fixed effects meta-analysis to obtain summary treatment effects, overall and across key subgroups. RESULTS: During median follow-up of 2.2 years across both trials, 740 of 8483 (8.7%) patients discontinued RAS blockade. The relative risk for discontinuation of RAS blockade was 15% lower in patients randomized to receiving SGLT2 inhibitors (HR, 0.85; 95% CI, 0.74 to 0.99), with consistent effects across trials ( P -heterogeneity = 0.92). The relative effect on RAS blockade discontinuation was more pronounced among patients with baseline urinary albumin:creatinine ratio ≥1000 mg/g (pooled HR, 0.77; 95% CI, 0.63 to 0.94; P -heterogeneity = 0.009). CONCLUSIONS: In patients with albuminuric CKD with and without type 2 diabetes, SGLT2 inhibitors facilitate the use of RAS blockade. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT02065791 and NCT03036150 . PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2023_11_21_JASN0000000000000248.mp3.
引用
- Fletcher RA, Jongs N, Chertow GM, et al. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. J Am Soc Nephrol. 2023. PMID: 37876229. doi:10.1681/ASN.0000000000000248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。